Novartis has submitted NVA237, the company’s new treatment for chronic obstructive pulmonary disease, for approval in Japan.
The drug, which was submitted for European approval in September 2011 under the brand name Seebri Breezhaler, is a long-acting muscarinic antagonist designed to be taken once-daily.
Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.
